GENB Generate Biomedicines, Inc.

GENB Generate Biomedicines, Inc.

Healthcare · Biotechnology

Market read

POC $12.70 · VWAP $14.75 · -15.8% vs 12m avg buyer

too-young gaps: stablechurn: quiet as of

Insiders quiet 0 buy / 0 sell · Form 4, 90d

Coverage

1 related campaign

Watchlists @biotech-capital-cycle

GENB Price Structure

Loading chart…

Loading timeframes…

Peers

Every watchlist GENB belongs to, members best 30-day change first — GENB highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.

@biotech-capital-cycle
View watchlist →
NAUT+239.7% +24.6%1d +57.3%7d QSI+84.5% +21.7%1d +25.0%7d PACB+49.6% +2.4%1d +22.0%7d CRL+24.5% +1.7%1d +15.1%7d FTRE+21.1% -1.2%1d +5.1%7d CERT+19.6% +2.4%1d +10.3%7d AVTR+17.1% +0.8%1d +5.3%7d DNA+16.4% +2.9%1d -2.7%7d ICLR+13.0% -0.1%1d +8.9%7d MTD+11.9% -0.8%1d +3.0%7d RVTY+11.7% +0.9%1d +4.0%7d SEER+9.4% 0.0%1d -3.0%7d MEDP+8.4% +2.3%1d +8.2%7d AGIO+8.2% -0.5%1d +18.1%7d WAT+7.9% -0.4%1d +3.8%7d ILMN+5.5% 0.0%1d +2.6%7d A+4.7% -0.5%1d +0.1%7d IQV+4.3% +0.4%1d +4.7%7d DHR+4.0% +0.3%1d +0.6%7d TMO+1.3% -0.4%1d -2.3%7d RXRX0.0% +3.4%1d +6.6%7d BRKR-3.5% +0.5%1d +5.1%7d XBI-3.6% -1.4%1d +3.6%7d ABCL-4.0% +4.0%1d +0.2%7d RGEN-4.1% -1.0%1d +0.9%7d ALMR-4.5% +3.3%1d +21.4%7d TXG-5.4% +2.6%1d +2.4%7d ABSI-5.8% -2.0%1d +11.3%7d CDXS-7.3% -2.3%1d +3.2%7d QTRX-9.5% +0.7%1d -0.3%7d TEM-11.7% +6.0%1d +4.5%7d TWST-11.7% +3.3%1d +5.4%7d LAB-18.4% -4.7%1d -3.7%7d SDGR-18.6% +5.3%1d +5.3%7d GENB-24.9% -3.0%1d +2.6%7d VKTX-41.4% -5.5%1d -3.1%7d

Next earnings GENB reports in 13 days Nov 5

Last report Aug 6

Reported the quarter ending 2026-06-30: revenue $6M, diluted EPS -$0.52, net income -$67M (SEC filing). Across the print the stock moved -1.0% (close before → first close after).

full note →

Against street estimates

How GENB's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. A consensus out of line with the name's earlier estimates (opposite sign to all of them and over 3x their size) is not graded. EPS only.

2 quarters on file · newest report Aug 6 · projection Oct 23

Result
Aug 6 -0.49-0.52-5.6%Miss
May 7 -0.51-1.07-111.2%Miss

Recent news

Headlines about GENB from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.

pulled 9 days ago · Oct 14

GENB research tape

2 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.

earnings GENB earnings — 2026-08-06 deep dive GENB — Deep Dive (Generate Biomedicines)
Types
Aug 6 Catalyst GENB earnings
GENB
Jun 4 Deep Dive GENB (Generate Biomedicines)
GENB#biotech-capital-cycle